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Background: Randomized controlled trials have shown that dexamphetamine sulfate (DEX) is efficacious in the treatment 
of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents; however, data on the effectiveness and safety 
of DEX in routine practice are scarce. 
Objective: This study investigated the long-term effectiveness and safety of Attentin® (immediate-release DEX) in children 
and adolescents with ADHD in routine practice. 
Methods: ATTENTION was a multicenter, prospective, observational, non-interventional study that enrolled pediatric 
patients with ADHD (aged 6-17 years) with a clinically inadequate response to previous methylphenidate (MPH) treatment. 
Patients were assessed at baseline and two follow-up visits after approx. 6 and 12 months of DEX treatment. The primary 
endpoint was the investigator-rated ADHD rating scale IV (ADHD-RS-IV) total score change from baseline to the first 
follow-up visit. 
Results: The study enrolled 140 patients (mean age: 11.2 years). Significant reductions in ADHD-RS-IV total scores were 
observed in the titration phase and were maintained up to the second follow-up visit. The mean ADHD-RS-IV total score 
change from baseline to the first follow-up visit was -11.9 (27.1 vs. 13.4, p < .001). Beneficial effects of DEX were observed 
on both ADHD-RS-IV subscales (‘hyperactivity/impulsivity’ and ‘inattention’) and in both children and adolescents. Clinical 
response, defined as a reduction in the ADHD-RS-IV total score of at least 30% at the first follow-up visit, was observed in 
78.1% of patients. Patients reported an average onset of action of 36.2 minutes and an average duration of action of 6.5 hours 
after intake of the first dose of DEX in the morning. DEX was well tolerated. Small significant increases in mean systolic and 
diastolic blood pressure compared to baseline were observed. 
Conclusions: Attentin® is an effective and well-tolerated long-term treatment for pediatric ADHD patients with a clinically 
inadequate response to previous MPH treatment. 
 




Attention-deficit/hyperactivity disorder (ADHD) is 
one of the most common neurodevelopmental 
disorders of childhood, with an estimated worldwide 
prevalence of 7.2% in children ≤18 years (1). 
According to the Diagnostic and Statistical Manual 
of Mental Disorders, Fifth Edition (DSM-5), ADHD 
is characterized by the core symptoms of inattention, 
hyperactivity and impulsivity that negatively impact 
social and academic/occupational functioning (2). 
The International Statistical Classification of 
Diseases and Related Health Problems, Tenth 
Revision (ICD-10) refers to ADHD as Hyperkinetic 
Disorder and provides generally similar but stricter 
criteria for the diagnosis of the disorder (3).  
Current practice guidelines recommend a 
comprehensive multimodal treatment approach for 
the management of ADHD (4-7). Stimulants, 
including methylphenidate (MPH) and 
amphetamines (AMP), are the most commonly used 
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pharmacological treatment. Numerous randomized 
controlled trials (RCTs) and meta-analyses have 
demonstrated the efficacy and safety of stimulants 
for the treatment of ADHD in children and 
adolescents (8-12).  
The exact mechanism of action of stimulants in 
humans with ADHD is not fully known, however, it 
is thought that both MPH and AMP increase levels 
of extracellular dopamine (DA) and norepinephrine 
(NE) in the synaptic cleft and thereby enhance 
noradrenergic and dopaminergic neurotransmission 
in the central nervous system (13). Both MPH and 
AMP inhibit the dopamine transporter (DAT) and 
norepinephrine transporter (NET) (14), resulting in 
increased extracellular DA and NE levels (13). In 
contrast to MPH, AMP also promotes the release of 
DA from the presynaptic neuron into the synaptic 
cleft (Supplementary Figure S1) (13, 15-17).  
Various amphetamine products are currently 
marketed for the treatment of ADHD, including oral 
immediate-release and extended-release formulations 
containing different AMP salts and stereoisomers 
(18). Attentin/Amfexa/Tentin® is an immediate-
release tablet formulation of dexamphetamine sulfate 
that is available at doses of 5 mg, 10 mg and 20 mg 
(19). The product was first authorized in Germany in 
2011 and has subsequently been approved in several 
further countries (Supplementary Table S1). For 
simplicity, the following sections refer to the product 
as Attentin®. 
Attentin® is indicated as part of a comprehensive 
treatment program for ADHD in children and 
adolescents aged 6 to 17 years when response to 
previous methylphenidate treatment is considered 
clinically inadequate. A comprehensive treatment 
program typically includes psychological, educational 
and social measures. Diagnosis should be made 
according to DSM-5 criteria or the guidelines in 
ICD-10 and should be based on a comprehensive 
multidisciplinary evaluation of the patient. DEX is 
not indicated in all children with ADHD and the 
decision to use DEX must be based on a very 
thorough assessment of the severity and chronicity 
of the child’s symptoms in relation to the child’s age 
and potential for abuse, misuse or diversion. 
Treatment should be under the supervision of a 
specialist in childhood and/or adolescent behavioral 
disorders (19). 
Careful dose titration is necessary at the start of 
treatment with DEX. Dose titration should be 
started at the lowest possible dose. The 
recommended starting daily dose is 5 mg once or 
twice daily (e.g. at breakfast and lunch), increasing if 
necessary by weekly increments of 5 mg in the daily 
dose according to tolerability and degree of efficacy 
observed. The regimen that achieves satisfactory 
symptom control with the lowest total daily dose 
should be employed. The maximum daily dose in 
children and adolescents usually is 20 mg, although 
doses of 40 mg may in rare cases be necessary for 
optimum titration (an overview of the dosing 
recommendations is given in Supplementary Figure 
S2) (19). 
The pharmacokinetic properties of Attentin® 
tablets were assessed in 18 healthy adults. Following 
the administration of one 5 mg tablet, average 
maximal plasma concentrations (Cmax) of 11.5 
ng/mL were achieved at a mean ± SD tmax of 1.5 ± 
0.4 hours (Supplementary Figure S3) (19).  
Several studies have demonstrated the superiority 
of DEX over placebo in improving core symptoms 
and functional outcomes in pediatric patients with 
ADHD. DEX was also shown to have equivalent 
efficacy compared to other stimulants (20-26). A 
network meta-analysis that assessed the comparative 
efficacy and tolerability of oral ADHD medications 
supports MPH in children and adolescents, and 
amphetamines in adults, as first-choice medications 
for short-term ADHD treatment (27). A review of 
response data from studies directly comparing MPH- 
and AMP-based stimulants found that 71% of 
patients responded to MPH, 68% responded to 
AMP, and 91% responded to either type of stimulant 
(28). These data indicate that, although the response 
rates to MPH and AMP are similar in the overall 
population, individual response to either class of 
stimulant may vary, i.e. some individuals respond 
better to MPH and some respond better to AMP. 
Thus, if an ADHD patient does not respond to or 
does not tolerate one type of stimulant, the other 
type of stimulant should be tried. 
The safety profiles of different stimulant classes 
and formulations are generally comparable (18). A 
recent Cochrane review found that the most 
common adverse events (AEs) reported in RCTs of 
pediatric ADHD patients treated with AMP 
products included decreased appetite, 
insomnia/trouble sleeping, abdominal pain, 
nausea/vomiting, headaches, and anxiety (9). Most 
AEs are mild and/or temporary and can be managed 
by the clinician through dose and timing adjustments 
(29). In most cases, medication discontinuation is not 
necessary (30). Serious side effects are rare and 
disappear when the dose is reduced or treatment is 
discontinued (29).  
RCTs are considered the gold standard of 
evidence-based medicine, providing the highest level 
of evidence on clinical efficacy and safety of 
therapeutic interventions. However, most RCTs 
have strict inclusion criteria, meaning that the trial 
populations are highly homogeneous and often not 
representative of the prevailing patient population in 
a real-world community-based setting. Real-world 
studies can complement the results from RCTs by 





providing data on the treatment effectiveness in 
heterogeneous patient populations encountered in 
routine clinical practice (31).  
The non-interventional study (NIS) 
ATTENTION (Attentin® in children and 
adolescents with ADHD – a non-interventional 
study) investigated the real-world effectiveness and 





The objective of the study was to investigate the 
long-term effectiveness and safety of DEX treatment 




The study included children/adolescents between 6 
and 17 years with a confirmed ADHD diagnosis 
(according to DSM-IV/5 or ICD-10) who had a 
clinically inadequate response to previous MPH 
treatment. The indication for DEX treatment was at 
the discretion of the treating physician. Patients with 
contraindications to Attentin® were excluded. All 
patients/caregivers provided written informed 
consent to participate.  
 
Study design 
This was a multicenter, prospective, observational, 
non-interventional study (ClinicalTrials.gov 
Identifier: NCT02801604). The necessary ethics 
approvals were obtained before study start. The 
study was conducted between June 2016 and April 
2019. Overall, 40 study centers (37 in Germany and 
one each in Denmark, Norway and Sweden) 
participated in the study; all participating sites were 
specialized in childhood and/or adolescent 
behavioral disorders. The study consisted of a 
baseline visit (baseline examinations and 
retrospective assessment of efficacy and safety of 
previous ADHD medications; V1), a titration phase 
to determine the optimal dose of DEX, and a 
maintenance phase that included two follow-up visits 
after approx. 6 months (V2) and 12 months (V3) of 
DEX treatment. All decisions regarding treatment of 
patients (e.g. initial dose, titration scheme, follow-up) 
were at the sole discretion of the treating physician. 
The study protocol recommended that Attentin® be 




The primary efficacy variable was the ADHD rating 
scale IV (ADHD-RS-IV), a validated instrument for 
assessing the severity of ADHD symptoms in 
children and adolescents. The ADHD-RS-IV is an 
18-item scale based on the ADHD symptoms 
described in the DSM-IV. Each item is rated on a 4-
point Likert scale ranging from 0 (none) to 3 (severe) 
(32). The primary endpoint was defined as the 
investigator-rated ADHD-RS-IV total score change 
from V1 to V2. 
Secondary endpoints included ADHD-RS-IV total 
score changes from V1 to titration and from V1 to 
V3, as well as changes from V1 in ADHD-RS-IV 
subscales. Further secondary endpoints included 
subgroup analyses of the primary endpoint stratified 
by gender, total daily DEX dose and baseline 
ADHD-RS-IV total score. Additionally, the primary 
and all secondary endpoints were stratified by age 
group (children and adolescents). The DEX dose as 
well as the onset of action and duration of action of 
DEX were also assessed. The overall burden of 
impairments in daily functioning on the parents or 
family was assessed using a 4-point Likert question 
ranging from 0 (not at all) to 3 (a great deal). 
Compliance to treatment was estimated using a 5-
point Likert question (1 = 100% compliance, 2 = 
≥90%, 3 = ≥75% and <90%, 4 = ≥50% and <75%, 
5 = <50%). 
 
Safety 
Adverse drug reactions (ADRs) were recorded by the 
physician at each study visit. The safety of the last 
ADHD medication was retrospectively assessed at 
the baseline visit (ADRs in the previous 6 months 
before initiation of DEX). Weight, height, blood 
pressure and heart rate were assessed at each study 
visit. Any signs of drug abuse, drug dependency, 




All clinical data were captured in electronic case 
report forms (Clincase, Quadratek Data Solutions 
Ltd, Berlin, Germany). The software complied with 
Good Clinical Practice (GCP) and international 
standards for capturing study data. 
All enrolled patients were included in the statistical 
analysis. For the calculation of ADHD-RS-IV 
total/subscale scores and the response rate, only 
complete cases were used (no imputation of missing 
values). Responders were defined as patients with a 
relative reduction in the ADHD-RS-IV total score 
from V1 to V2 of at least 0.3 (i.e. 30%).  
Differences in ADHD-RS-IV total scores were 
assessed using a two-sided paired t-test. The 
correlation between total daily dose and age or 
weight was analyzed using Pearson’s correlation 
coefficient (r). All analyses were performed using 
SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and R 
4.0.2 (R Foundation for Statistical Computing, 
Vienna, Austria) with the R-package haven (33, 34). 





Body mass index (BMI) z-scores were calculated 
based on the WHO growth reference data for 5 to 19 





A total of 140 patients were enrolled in the study and 
included in the statistical analyses. Most of the 
patients were included in Germany (N=133, 95.0%); 
four (2.9%) patients were included in Denmark, two 
(1.4%) in Norway and one (0.7%) in Sweden.  
Demographic and other baseline characteristics 
All enrolled patients attended V1, 138 (98.6%) 
patients attended the titration visits, 98 (70%) 
patients attended V2 and 89 (63.6%) patients 
attended V3. The most common reasons for 
discontinuing DEX treatment included 
noncompliance of the patients (n=12, 8.6%), 
insufficient efficacy, and ADRs (n=10; 7.1% each). 
Demographic and other baseline characteristics of 




TABLE 1. Baseline demographics and disease characteristics 
Characteristic  
Age (years)  
 Mean ± SD 11.2 ± 3.1 
 Median (minimum, maximum) 11.0 (6, 17) 
Age group, n (%)  
 Children (<12 years) 82 (58.6) 
 Adolescents (≥12 years) 58 (41.4) 
Race, n (%)  
 White 140 (100.0) 
Sex, n (%)  
 Male 100 (71.4) 
 Female 40 (28.6) 
Time since ADHD diagnosis (months), median (IQR) (N=138) 22.0 (44.5) 
ADHD diagnosis according to   
 ICD-10 138 (98.6) 
 DSM-5 1 (0.7) 
 DSM-IV 1 (0.7) 
ADHD diagnosis according to ICD-10, n (%)  
 F90.0: disturbance of activity and attention 97 (69.3) 
 F90.1: hyperkinetic conduct disorder 38 (27.1) 
 F90.9: hyperkinetic disorder, unspecified 3 (2.1) 
ADHD diagnosis according to DSM-5, n (%)  
 314.01: combined presentation 1 (0.7) 
ADHD diagnosis according to DSM-IV, n (%)  
 314.01: predominantly hyperactive/impulsive type 1 (0.7) 
Additional conduct disorder, n (%) 61 (43.6) 
Concomitant diseases, n (%) (n≥3)  
 All  53 (37.9) 
 Autism spectrum disorder  9 (6.4) 
 Disturbance in social behavior  7 (5.0) 
 Depression  5 (3.6) 
 Enuresis  4 (2.9) 
 Sleep disorder  4 (2.9) 
 Tic  3 (2.1) 
Notes. ADHD: Attention-deficit/hyperactivity disorder; DSM-IV/5: Diagnostic and Statistical 
Manual of Mental Disorders IV/5; ICD-10: International Statistical Classification of Diseases 
and Related Health Problems, Tenth Revision; IQR: Interquartile range; n: Number of 










TABLE 2. Characteristics of treatment with previous MPH medications and DEX 
Previous MPH treatment 
Number of MPH therapies, n (%) (N=137)  
 1 118 (86.1) 
 2 15 (11.0) 
 3 3 (2.2) 
 5 1 (0.7) 
Number of single doses per day, mean ± SD (N=137) 1.4 ± 0.5 
 Immediate-release (N=33) 1.5 ± 0.6 
 Extended-release (N=114) 1.4 ± 0.5 
Total daily MPH dose (mg), mean ± SD (N=137) 27.5 ± 14.1 
 Immediate-release (N=33) 20.7 ± 12.2 
 Extended-release (N=114) 28.9 ± 14.0 
DEX treatment  
Total daily dose at the respective visit (mg), median (IQR)  
 First titration visit (initial dose) (N=138) 5.0 (5.0) 
  Children (<12 years) (N=80) 5.0 (5.0) 
  Adolescents (≥12 years) (N=58) 5.0 (5.0) 
 Titration (last recorded dose) (N=138) 11.3 (10.0) 
  Children (<12 years) (N=80) 10.0 (10.6) 
  Adolescents (≥12 years) (N=58) 15.0 (10.0) 
 V2 (N=95) 12.5 (10.0) 
  Children (<12 years) (N=57) 10.0 (10.0) 
  Adolescents (≥12 years) (N=38) 15.0 (10.0) 
 V3 (N=82) 15.0 (10.0) 
  Children (<12 years) (N=53) 12.5 (10.0) 
  Adolescents (≥12 years) (N=29) 20.0 (10.0) 
Optimal total daily dose (mg), median (IQR) (N=120) 10.0 (10.0) 
 Children (<12 years) (N=69) 10.0 (10.0) 
 Adolescents (≥12 years) (N=51) 15.0 (10.0) 
Optimal total daily dose per body weight (mg/kg), median (IQR) (N=120) 0.3 (0.3) 
 Children (<12 years) (N=69) 0.4 (0.3) 
 Adolescents (≥12 years) (N=51) 0.3 (0.2) 
Number of titration steps to optimal total daily dose, n (%) (N=140)  
 1  16 (11.4) 
 2 46 (32.9) 
 3 24 (17.1) 
 4 22 (15.7) 
 5 4 (2.9) 
 6 7 (5.0) 
 10 1 (0.7) 
 Optimal total daily dose not achieved 18 (12.9) 
 No titration performed 2 (1.4) 
Dose regimen, n (%) (N=129)  
 Once daily 76 (58.9) 
 Twice daily 50 (38.8) 
 Three times daily 2 (1.6) 
 Four times daily 1 (0.8) 










The mean age was 11.2 years (range, 6-17 years); 82 
(58.6%) patients were classified as children (<12 
years) and 58 (41.4%) patients were classified as 
adolescents (≥12 years). Most patients (n=100, 
71.4%) were male.  
All but two patients (98.6%) were diagnosed based 
on ICD-10 criteria, with 69.3% of patients having a 
disturbance of activity and attention (ICD-10 code 
F90.0), which corresponds to the predominantly 
inattentive presentation of ADHD according to 
DSM-5, and 27.1% of patients having a hyperkinetic 
conduct disorder (ICD-10 code F90.1), which 
corresponds to the predominantly 
hyperactive/impulsive presentation (2). 
The median (interquartile range [IQR]) time since 
ADHD diagnosis was 22.0 (44.5) months. Overall, 
53 (37.9%) patients had concomitant psychiatric or 
physical diseases. The most frequent psychiatric 
disorders included autism spectrum disorder (n=9, 
6.4%), disturbance in social behavior (n=7, 5.0%) 
and depression (n=5, 3.6%). Concomitant therapies 
were used by 21 (15.0%) patients. Medications used 
by more than two patients included antidepressants 
(n=6, 4.3%), antipsychotics (n=4, 2.9%) and 
hypnotics and sedatives (n=2, 1.4%). Seven patients 
received non-drug therapies, most commonly 
behavior therapy and occupational therapy (n=2, 
1.4% each). Previous or current ADHD medications 
were documented for 139 (99.3%) patients. All 
patients had used MPH products as per the inclusion 
criteria. Further commonly used ADHD medications 
included lisdexamfetamine (n=36; 25.7%), 
atomoxetine (n=22, 15.7%) and guanfacine (n=6, 
4.3%). 
 
Treatment with MPH and DEX 
Main treatment characteristics are summarized in 
Table 2. Data on the previous/current MPH 
medications were collected at V1. Most patients 
(n=118, 86.1%) had one recorded MPH therapy, 15 
(11.0%) patients had two MPH therapies, three 
(2.2%) patients had three MPH therapies, and one 
(0.7%) patient had five MPH therapies. The mean 
total daily MPH dose was 27.5 ± 14.1 mg/d (ranging 
from 5.0 to 80.0 mg/d). The mean doses for 
extended-release preparations were higher than those 
for immediate-release preparations (Table 2). 
Overall, the reasons (multiple answers possible) for 
switching from the previous ADHD medication to 
DEX were insufficient efficacy in 110 (79.1%) 
patients, short duration of action of current drug in 
47 (33.8%) patients, insufficient tolerability in 25 
(18.0%) patients and other reasons in 16 (11.5%) 
patients.   
The median (IQR) initial total daily DEX dose was 
5.0 (5.0) mg/d. At the end of the titration phase, the 
last recorded total daily dose was 11.3 (10.0) mg/d. 
The total daily dose was 12.5 (10.0) mg/d at V2 and 
15.0 (10.0) mg/d at V3. 
At the first titration visit, most patients used an 
initial total daily dose of 5 mg/d (n=62, 45.0%) or 10 
mg/d (n=46, 33.3%). Four (2.9%) patients used 20 
mg/d and one (0.7%) patient used 60 mg/d. At V2, 
the most commonly used doses were 10 mg/d 
(n=26, 27.4%) or 15 mg/d (n=21, 22.1%), and at V3 
the most commonly used doses were 10.0 mg/d 
(n=21, 25.6%) or 20 mg/d (n=17, 20.7%). 
At the initial titration visit, the median (IQR) total 
daily dose was 5.0 (5.0) mg/d for both children and 
adolescents, however, adolescents received a higher 
median total daily dose compared to children at end 
of titration, V2 and V3 (Table 2). 
At V1, the total daily dose correlated with age (r = 
0.17, p = .04) and with weight (r = 0.23, p = .01). At 
V2, positive correlation coefficients of the same 
magnitude were observed (total daily dose and age: r 
= 0.16, p = .12; total daily dose and weight: r = 0.17, 
p = .09). However, they are not significant at the 5% 
level due to the sample size, likewise at V3 (total daily 
dose and age: r = 0.09, p = .43; total daily dose and 
weight: r = 0.16, p = .15). 
Two titration steps were performed in 46 (32.9%) 
patients, three titration steps were performed in 24 
(17.1%) patients, and four titration steps were 
performed in 22 (15.7%) patients. The optimal daily 
dose was not achieved in 18 patients and no titration 
was performed in two patients. DEX was most 
commonly administered once daily (n=76, 58.9%) or 
twice daily (n=50, 38.8%). The dose regimen was not 
documented for 11 patients. 
DEX was used in combination with other ADHD 
medications in 29 (20.7%) patients. Combination 
therapy was used in 15 (10.7%) patients at V1, 22 
(15.7%) patients at V2 and four (2.9%) patients at 
V3. Most patients used risperidone (n=12, 8.6%), 




The mean ADHD-RS-IV total score decreased from 
27.1 ± 11.7 at V1 to 13.4 ± 9.1 at V2. The mean 
change in the ADHD-RS-IV total score from V1 to 
V2 was -11.9 (95% confidence interval [CI]: -14.0 to 
-9.7; p < .001) (Figure 1). 
Decreases in ADHD-RS-IV total scores compared 
to baseline were also observed at the last titration 
visit (14.9 ± 10.1) and at V3 (12.3 ± 8.5). The mean 
change from V1 to the last titration visit was -11.8 
(95% CI: -13.4 to -10.1; p < .001) and the mean 
change to V3 was -12.7 (95% CI: -15.1 to -10.4; p 
< .001). 
Statistically significant improvements (p < .001) 
were observed for both ADHD-RS-IV subscale 




























FIGURE 1. Mean ADHD-RS-IV total scores from baseline to study end. Data are shown as mean ± SEM. 
 
 
TABLE 3. ADHD-RS-IV total and subscale score changes during the study and subgroup analyses stratified by age group (children and 
adolescents) 
Subgroup V1 (previous MPH 
treatment) 
 Δ V2 – V1  Δ V3 – V1 
 N  Mean ± SD  N Mean ± SD p  N  Mean ± SD p 
Total population           
ADHD-RS-IV total score 136 27.1 ± 11.7  96 -11.9 ± 10.8 < .001  85 -12.7 ± 10.9 < .001 
ADHD-RS-IV subscale 
hyperactivity/impulsivity 
136 11.1 ± 7.3  96 -5.0 ± 6.1 < .001  85 -5.7 ± 5.8 < .001 
ADHD-RS-IV subscale inattention 136 16.0 ± 5.4  97 -6.8 ± 5.6 < .001  85 -7.1 ± 5.9 < .001 
Subgroup analysis according to age 
group 
          
ADHD-RS-IV total score            
 Children 80 27.7 ± 12.9  58 -11.7 ± 11.7 < .001  54 -12.8 ± 11.3 < .001 
 Adolescents 56 26.2 ± 9.8  38 -12.1 ± 9.3 < .001  31 -12.5 ± 10.3 < .001 
ADHD-RS-IV subscale 
hyperactivity/impulsivity  
          
 Children 80 11.8 ± 8.2  58 -5.0 ± 6.8 < .001  54 -6.0 ± 6.0 < .001 
 Adolescents 56 10.0 ± 5.6  38 -5.1 ± 4.9 < .001  31 -5.1 ± 5.4 < .001 
ADHD-RS-IV subscale inattention           
 Children 80 15.9 ± 5.7  59 -6.7 ± 5.6 < .001  54 -6.9 ± 6.0 < .001 
 Adolescents 56 16.1 ± 5.1  38 -7.0 ± 5.6 < .001  31 -7.4 ± 5.9 < .001 
Notes. MPH: Methylphenidate; N: Number of patients; SD: Standard deviation 
Only complete ADHD total scores were used; p-value based on t-test for paired samples 
 
 






TABLE 4. Subgroup analyses of ADHD-RS-IV total score changes during the study 
Subgroup V1 (previous MPH 
treatment) 
 Δ V2 – V1  Δ V3 – V1 
 N ADHD-RS-IV total 
score (mean ± SD) 
 N ADHD-RS-IV total score 
(mean ± SD) 
p  N ADHD-RS-IV total 
score (mean ± SD) 
p 
Gender           
 Male 98 27.6 ± 12.1  69 -12.8 ± 11.2 < .001  64 -13.3 ± 10.9 < .001 
 Female 38 25.8 ± 10.8  27 -9.4 ± 9.3 < .001  21 -11.1 ± 10.8 < .001 
Maximum total daily 
DEX dose (mg/d) 
          
 ≤10 62 28.4 ± 10.8  46 -13.0 ± 11.0 < .001  40 -14.7 ± 11.2 < .001 
 >10 to ≤20 51 28.2 ± 12.9  34 -10.4 ± 12.3 < .001  28 -11.3 ± 11.5 < .001 
 >20 22 20.4 ± 9.8  16 -11.7 ± 4.7 < .001  17 -10.5 ± 8.5 < .001 
Baseline ADHD-RS-IV 
total score 
          
 ≤20 45 13.4 ± 3.0  40 -4.5 ± 8.7 .002  36 -5.1 ± 7.0 < .001 
 >20 to ≤40 71 30.5 ± 5.1  41 -15.0 ± 7.9 < .001  37 -16.6 ± 9.3 < .001 
 >40 20 45.7 ± 3.9  15 -22.8 ± 9.1 < .001  12 -23.8 ± 9.4 < .001 
Notes. ADHD-RS-IV: ADHD rating scale IV; DEX: Dexamphetamine; MPH: Methylphenidate; N: Number of patients; SD: Standard deviation 




































FIGURE 2. Overall burden of impairments in daily functioning during the study period.  










scores at all assessed time-points. The mean change 
from V1 in hyperactivity/impulsivity scores was -5.1 
(95% CI: -6.0 to -4.2) at titration, -5.0 (95% CI: -6.3 
to -3.8) at V2 and -5.7 (95% CI: -6.9 to -4.4) at V3. 
The mean change from V1 in inattention scores was 
-6.7 (95% CI: -7.6 to -5.8) at titration, -6.8 (95% CI: 
-7.9 to -5.7) at V2 and -7.1 (95% CI: -8.3 to -5.8) at 
V3 (Table 3). 
Subgroup analyses of the ADHD-RS-IV total 
score and subscale scores stratified by age group 
found significant beneficial effects of DEX in both 
children and adolescents (Table 3). 
Treatment response was defined as a reduction in 
the ADHD-RS-IV total score of at least 30% from 
V1 to V2. According to this definition, the response 
rate was 78.1% (75/96). The mean reduction in the 
ADHD-RS-IV total score from V1 to V2 was 43%. 
A dose-response relationship was not observed. The 
response rates were similar for patients treated with 
≤10 mg (72.0%, 36/50) or >10 to ≤20 mg (78.1%, 
25/32). For patients treated with >20 mg, the 
response rate was 100% (14/14). Subgroup analyses 
indicated that the response rates were comparable 
between children and adolescents (79.3% [46/58] vs. 
76.3% [29/38]). For doses ≤10 mg, the response rate 
was 72.7% (24/33) in children and 70.6% (12/17) in 
adolescents, for doses >10 mg to ≤20 mg, the 
response rate was 81.3% (13/16) in children and 
75.0% (12/16) in adolescents. For doses >20 mg, the 
response rate was 100% in both children (9/9) and 
adolescents (5/5). 
The results of subgroup analyses of the primary 
endpoint were consistent when stratified by gender, 
maximum total daily DEX dose and baseline 
ADHD-RS-IV total score. Significant reductions in 
ADHD-RS-IV total scores from V1 to V2 were 
observed in all analyzed subgroups. No differences 
in ADHD-RS-IV total scores at V2 were observed in 
subgroups stratified by gender or maximum total 
daily DEX dose. However, the baseline ADHD-RS-
IV total score appears to influence the degree of 
symptom improvement at V2. The mean change in 
ADHD-RS-IV total scores was higher for patients 
with a baseline ADHD-RS-IV score of >40 (-22.8 
[95% CI: -27.8 to -17.8]; p < .001) compared to 
patients with a baseline ADHD-RS-IV score of >20 
to ≤40 (-15.0 [95% CI: -17.5 to -12.5]; p < .001) or 
≤20 (-4.5 [95% CI: -7.3 to -1.7]; p = .002) (Table 4). 
Significant reductions in ADHD-RS-IV total 
scores from V1 were also observed at titration and 
V3 (Table 4) in all subgroups. 
Patients estimated the onset of action and duration 
of action of DEX after intake of the study drug in 
the morning. The mean onset of action was 36.2 
minutes and the mean duration of action was 6.5 
hours. 
DEX treatment reduced the overall burden of 
functional impairment due to ADHD in most 
patients. At V1, 70.3% (97/138) of patients reported 
“quite a lot” and 23.9% (33/138) of patients reported 
“a great deal” of burden of impairment, whereas at 
V3, this was the case for 15.1% (13/86) and 1.2% 
(1/86) of patients, respectively, with most patients 
reporting “only a little” (70.9% [61/86]) or “no” 
(12.8% [11/86]) burden of impairment (Figure 2). 
Overall, the burden of impairment was improved for 
74 patients, unchanged for 11 patients and worse for 
one patient at V3 compared to V1. 
At baseline, a treatment compliance of ≥90% was 
documented for 74.6% (103/138) of patients treated 
with MPH and 79.6% (43/54) of patients treated 
with non-MPH ADHD medications. Comparable 
compliance rates were observed for DEX over the 
whole study period, with 77.6% (76/98) of patients 
at V2 and 80.5% (70/87) of patients at V3 having a 
treatment compliance of ≥90%. 
 
Safety 
Overall, 114 ADRs to ADHD medications 
(including previous medications) were documented 
for 39 patients during the course of the study. 
Forty-six ADRs to DEX were reported in 19 
patients. The most common ADRs were decreased 
appetite (n=7) and depressed mood (n=3) (Table 
S2). Most ADRs were of mild or moderate intensity; 
eight severe ADRs occurred in three patients 
(hyperacusis, crying, rebound effect, decreased 
appetite, abnormal behavior, apathy, depressed 
mood, and restlessness). 
From V1 to V3, a mean increase in height (5.7 ± 
2.9 cm, p < .001) and weight (3.6 ± 3.7 kg, p < .001) 
was observed. Compared to V1, the mean BMI z-
score was significantly decreased at V2 (-0.18 ± 0.49, 
p < .001) and V3 (-0.16 ± 0.63, p = .018) (Table 5). 
Small, statistically significant increases in mean 
systolic and diastolic blood pressure compared to 
baseline were observed throughout the study. At V3, 
mean systolic blood pressure was increased by 3.8 ± 
9.1 mmHg (p < .001) and mean diastolic blood 
pressure was increased by 3.8 ± 9.0 mmHg (p < .001) 
(Table 5). Seventeen patients who were classified as 
having “normal blood pressure” (<120/<80 mmHg) 
at V1 shifted to the “prehypertension” (120-139/80-
89 mmHg) category at V3. One patient who was 
prehypertensive at V1 shifted to the “stage 1 
hypertension” (140-159/90-99 mmHg) category at 
V3. No significant changes in heart rate were 
observed (Table 5). 
DEX was generally well tolerated during the course 
of the study. At V3, all patients (N=87, 100%) 
reported “no interference” of DEX with daily 
functioning. Compared to that, 91 (67.4%) patients  













TABLE 5. Changes in height, weight, BMI z-scores and vital signs during the study 
 V1  V2  V3  Δ V2 – V1  Δ V3 – V1 
 N Mean ± SD  N Mean ± SD  N Mean ± SD  N Mean ± SD p  N Mean ± SD p 
Height [cm] 140 147.7 ± 18.9  96 149.3 ± 17.1  86 151.8 ± 16.6  96 2.1 ± 2.1 < .001  86 5.7 ± 2.9 < .001 
Weight [kg] 140 42.7 ± 17.7  97 41.6 ± 15.6  87 43.4 ± 15.7  97 1.2 ± 2.7 < .001  87 3.6 ± 3.7 < .001 
BMI z-score 140 0.20 ± 1.20  96 -0.12 ± 1.08  86 -0.10 ± 1.11  96 -0.18 ± 0.49 < .001  86 -0.16 ± 0.63 0.018 
Systolic blood pressure 
[mmHg] 
140 112.1 ± 12.0  98 113.5 ± 11.9  87 114.3 ± 12.4  98 2.4 ± 9.6 0.017  87 3.8 ± 9.1 < .001 
Diastolic blood pressure 
[mmHg] 
140 71.5 ± 8.6  98 73.3 ± 8.4  87 74.7 ± 8.5  98 2.2 ± 8.8 0.016  87 3.8 ± 9.0 < .001 
Heart rate [beats/min] 140 79.9 ± 13.7  98 78.4 ± 12.0  87 80.1 ± 13.1  98 0.01 ± 9.5 ns  87 0.64 ± 13.0 ns 
Notes. BMI: Body mass index; N: Number of patients; ns: Not significant; SD: Standard deviation 









taking MPH and 27 (50.0%) patients taking 
medications other than MPH reported “no 
interference” under the respective medications. 
Furthermore, no indication for drug abuse, 




RCTs are considered the gold standard of evidence-
based medicine; however, RCTs usually have strict 
enrolment criteria and treatment protocols, meaning 
that the patient samples and treatment conditions are 
often not representative of real-world clinical 
practice. In contrast, observational, non-
interventional studies provide data on the 
effectiveness and tolerability of medications in 
routine clinical practice. The ATTENTION study 
was a prospective, observational, non-interventional 
study that investigated the effectiveness and safety of 
DEX treatment under routine conditions in pediatric 
ADHD patients with a clinically inadequate response 
to previous MPH treatment. DEX treatment 
significantly improved ADHD symptoms over the 
whole study period. The mean ADHD-RS-IV total 
score change from baseline to the first follow-up visit 
after approx. 6 months (primary endpoint) was -11.9 
(27.1 vs. 13.4, p < .001). Significant reductions in 
ADHD-RS-IV total scores were observed in the 
titration phase and were maintained up to the second 
follow-up visit after approx. 12 months of DEX 
treatment, indicating that the therapeutic 
effectiveness of DEX is maintained during long-term 
treatment in routine clinical practice. These findings 
are in line with results from a long-term, placebo-
controlled study conducted by Gillberg and 
colleagues that showed sustained efficacy of 
amphetamines in children with ADHD over a 
treatment period of 15 months (25). Furthermore, 
beneficial effects of DEX were observed on both 
ADHD-RS-IV subscales (‘hyperactivity/impulsivity’ 
and ‘inattention’) and in both children and 
adolescents. Patients with more severe ADHD 
symptoms at baseline appear to benefit the most 
from DEX treatment. 
The study population consisted of patients with a 
clinically inadequate response to MPH. A high 
response rate was observed in the study, with 78.1% 
of patients responding to DEX. These data confirm 
findings from other studies that have shown that 
some individuals respond preferentially to MPH 
whereas others respond preferentially to DEX (20, 
21, 26, 28), indicating that a trial of both MPH and 
DEX may increase the probability for a favorable 
response and optimal response strength for an 
individual patient. Therefore, in children with an 
unsatisfactory response to MPH, a trial of DEX 
should be considered. The response to DEX was not 
dose-dependent, which confirms findings from 
clinical trials and clinical experience that indicate that 
the dose needs to be individually titrated for each 
patient. 
Patients in this study reported an average onset of 
action of 36.2 minutes and an average duration of 
action of 6.5 hours after intake of the first dose of 
DEX in the morning. These findings are in line with 
results from earlier studies that reported a rapid onset 
of action of DEX in the 30 to 60 min range (35) and 
a duration of action in the 4 to 6 hour range (35-38). 
DEX was administered as a single dose in the 
morning by 58.9% of patients, suggesting that the 
reported duration of the therapeutic effect is 
sufficient for most patients, while 38.8% of patients 
administered two doses per day, presumably to 
extend the duration of action to the late afternoon 
and evening. Administering DEX twice or more daily 
is in line with the Attentin® label, which recommends 
that the times at which the doses are administered 
should be selected to provide the best effect when it 
is most needed to combat school and social 
behavioral difficulties (19). Current practice 
guidelines also note that immediate-release 
formulations of stimulants may be more suitable than 
extended-release formulations if flexible dosing 
regimens are needed (7). 
Overall, “insufficient efficacy” was reported as a 
reason for switching to DEX for 79.1% of patients, 
while “insufficient tolerability” was reported for 
18.0% of patients. The mean total daily MPH dose 
was 27.5 mg (ranging from 5.0 to 80.0 mg). One 
possible explanation for these findings is that the 
recommended up-titration to the maximum tolerable 
dose of MPH, as recommended by current practice 
guidelines (4), was not performed in all patients. 
Current ADHD treatment guidelines recommend 
optimizing MPH dosage to the patients’ individual 
needs (39). Clinicians should initiate treatment at a 
low dose and slowly increase the dose until maximum 
benefit with minimum adverse effects is achieved. 
These recommendations are based on studies that 
have shown a substantial interindividual variability in 
clinical response to MPH. It is also possible that 
patients who reported “insufficient tolerability” as 
reason for switching to DEX experienced intolerable 
ADRs, such as insomnia or weight loss, that 
precluded any further up-titration of MPH. 
DEX was generally well tolerated during the course 
of the study, and no new safety findings were 
identified. The most commonly reported ADRs to 
DEX were decreased appetite and depressed mood. 
Mean BMI z-scores significantly decreased during 
the study, however, the changes in BMI z-scores 
were not large enough to be clinically meaningful. A 
review of longitudinal studies investigating growth 
effects of stimulant treatment in children with 





ADHD found that stimulants led to modest 
reductions in expected height and weight, although 
these effects attenuated over time (40). More clinical 
studies are needed to elucidate the impact of 
stimulant treatment on final height and weight. 
Current practice guidelines recommend regular 
monitoring of weight and height in children and 
adolescents receiving stimulant treatment (4, 6-7). 
A statistically significant increase in mean systolic 
and diastolic blood pressure was observed during the 
study, whereas no significant changes in heart rate 
were observed. Small but significant increases in 
blood pressure and heart rate are well documented 
adverse effects of stimulant treatment in children and 
adults (27, 41-43). In a meta-analysis of 
cardiovascular effects of stimulants in adults, the 
mean increase in heart rate was 5.7 beats/min and the 
mean increase in systolic blood pressure was 2.0 
mmHg (43). Generally small increases in blood 
pressure (≤ 5 mmHg) and heart rate (≤ 10 
beats/min) have also been observed in children and 
adolescents treated with stimulants (44). However, a 
recent meta-analysis found no association between 
ADHD medications and risk of sudden 
death/arrhythmia, stroke, myocardial infarction and 
all-cause death, although some of the confidence 
intervals for the pooled risk ratios did not exclude 
modest elevated risks (45). Cardiovascular status, 
including blood pressure and heart rate, should be 
carefully and regularly monitored during stimulant 
treatment (4-6). 
The findings of this study should be interpreted in 
light of several limitations. The main limitation is the 
uncontrolled, open-label design, which may have 
introduced bias in the estimation of treatment 
effects. Furthermore, the small sample size may limit 
the validity and generalizability of study results. 
Another limitation is the potential for recall bias, as 
the data regarding previous ADHD/MPH treatment 
(including data on effectiveness and safety) were 
reported retrospectively by the patient at the baseline 
visit. Since the study only included patients with a 
clinically inadequate response to previous MPH 
treatment, the study results may not be generalized 
to a broader population of ADHD patients that 
includes e.g. treatment-naïve patients. Conversely, 
the patient population in this study is consistent with 
the population for which Attentin® is indicated 
according to the approved label, thus, the study 
population is likely similar to the patient population 
that is prescribed Attentin® in routine clinical 
practice. ADRs were not assessed in a structured 
fashion in this study, for example by using an adverse 
event checklist or questionnaire. This was an 
observational study that aimed to gain insights into 
the use of DEX in routine clinical practice; thus, 
additional diagnosis or monitoring procedures for 
the patient beyond the usual medical practice were 
not included in the observational study plan. 
Therefore, a specific adverse event questionnaire, 
that may not be a part of routine practice, was not 
employed in this study. Unsystematic documentation 
of ADRs through general inquiry prompts has 
several drawbacks, including reliance on 
patient/parent recall and potential misclassification 
of adverse events by the investigator, especially 
behavioral changes. Since no structured method was 
used for the collection of ADRs in this study, the 
incidence of ADRs may have been underestimated. 
Nevertheless, the ADRs observed in this study are in 
line with the known safety profile of stimulant 
medications. 
Future research on the treatment of ADHD should 
focus on providing insights into the long-term effects 
of stimulants, using randomized withdrawal trials, 
population-based studies with self-controlled 




The study shows that Attentin® is an effective and 
well-tolerated long-term treatment option for 
pediatric ADHD patients with a clinically inadequate 
response to MPH treatment. The results of this real-
world study conducted in a heterogeneous patient 
population under naturalistic treatment conditions 
complement the findings from randomized 
controlled trials of DEX in children and adolescents 
with ADHD. Furthermore, the high response rate 
achieved in this study confirms the findings from 
other studies that have shown that some individuals 
respond preferentially to MPH whereas others 
respond preferentially to DEX. Thus, in ADHD 
patients who do not respond to or do not tolerate 
MPH, treatment with DEX should be tried. 
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